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Abstract
Kaposi sarcoma-associated herpesvirus (KSHV) is an emerging pathogen and the causative agent 
of multiple cancers in immunocompromised patients. To date, there is no licensed prophylactic 
KSHV vaccine. In this study, we generated a novel subunit vaccine that incorporates four key 
KSHV envelope glycoproteins required for viral entry in diverse cell types (gpK8.1, gB, and 
gH/gL) into a single multivalent KSHV-like particle (KSHV-LP). Purified KSHV-LPs were similar 
in size, shape, and morphology to KSHV virions. Vaccination of rabbits with adjuvanted KSHV-
LPs generated strong glycoprotein-specific antibody responses, and purified immunoglobulins 
from KSHV-LP-immunized rabbits neutralized KSHV infection in epithelial, endothelial, 
fibroblast, and B cell lines (60–90% at the highest concentration tested). These findings suggest 
that KSHV-LPs may be an ideal platform for developing a safe and effective prophylactic KSHV 
vaccine. We envision performing future studies in animal models that are susceptible to KSHV 
infection, to determine correlates of immune protection in vivo.
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1. Introduction
Infection with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human 
herpesvirus-8 (HHV-8) is estimated to account for >44,000 new cancer cases and 20,000 
deaths globally every year [1]. KSHV is associated with the endothelial-based Kaposi 
sarcoma (KS) and two rare B cell-based lymphomas, primary effusion lymphoma and 
multicentric Castleman disease, as well as KSHV inflammatory cytokine syndrome [2–5], 
particularly in immunosuppressed patients. Unlike other HHVs, KSHV is not ubiquitous, but 
is highly prevalent in certain areas, such as sub-Saharan Africa, where KS is the leading 
cancer among people living with HIV/AIDS [1,2,6]. Despite the HIV/AIDS pandemic and 
KSHV endemicity in Africa, the Mediterranean region, and parts of South America, efforts 
to develop a prophylactic vaccine against KSHV and its associated malignancies have been 
limited, with no clinical prophylactic vaccine trial ever reported [7].
KSHV etiology provides a window of opportunity for a prophylactic vaccine, even in 
endemic areas. In Africa, other endemic HHVs achieve widespread transmission and latent 
infection within the first year of life, infecting up to 76% of children. In contrast, few to no 
children are infected with KSHV by this age or even by five years of age [8–10]. In other 
parts of the world, where KSHV exposure typically occurs during adulthood, transmission is 
so poor that either repeated viral contact, or immunodeficiency, is required to sustain KSHV 
at > 5% population-wide seroprevalence [11]. KSHV superinfection in immunocompetent 
people is also limited, suggesting that some immune protection is conferred among adults 
[11]. Thus, minimal priming of the immune system by a vaccine prior to infection may be all 
that is required to prevent KSHV infection and associated malignancies in developing 
countries and to possibly eradicate KSHV and associated malignancies from developed 
countries.
Like other HHVs, KSHV encodes five conserved glycoproteins: open reading frame [ORF] 
8 (gB), ORF22 (gH), ORF47 (gL), ORF39 (gM), and ORF53 (gN) [12,13]. In addition, 
KSHV also encodes for a unique glycoprotein, gpK8.1, which is the major immunodominant 
glycoprotein on the virion and is thought to modulate viral tropism for B cells [14]. In the 
current infection model, KSHV is thought to first attach to host cell receptors through 
gpK8.1, which then signals gH/gL to activate the gB fusogen [15]. This infection model is 
supported by experiments that used neutralizing antibodies (nAbs) against gpK8.1 or 
recombinant KSHV (rKSHV) deletion mutants lacking gpK8.1 [14,16], gB [17], or gH/gL 
[58] to define the role of each KSHV glycoprotein in infecting various cell types. Because 
these data suggest that different KSHV glycoproteins modulate viral tropism for different 
cell types, we reasoned that targeting a single glycoprotein with a prophylactic vaccine 
might not completely protect against infection of diverse cell types. Thus, we hypothesized 
that including gpK8.1, gB, and gH/gL complex in a single, potent, multivalent vaccine 
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candidate is necessary for eliciting nAbs that can block KSHV infection of diverse 
permissive human cell types.
Due to the oncogenic potential of KSHV DNA [3,18], live-attenuated KSHV or any form of 
inactivated KSHV cannot be used in humans. To circumvent this shortcoming, we herein 
describe the construction, assembly, and biochemical characterization of a single, 
multivalent virus-like particle (VLP) that incorporates four key glycoproteins as a candidate 
KSHV-like particle (KSHV-LP) vaccine. We show that wild-type New Zealand white rabbits 
immunized with adjuvanted-KSHV-LPs elicited strong nAbs that prevented in vitro KSHV 
infection of epithelial, endothelial, fibroblast, and B cell lines. These results highlight a 
novel vaccine approach with potential for clinical application as a prophylactic vaccine 
against KSHV infection and its associated malignancies.
2. Methods
2.1. Animals and ethic statement
Wild-type New Zealand white rabbits and wild-type BALB/c mice were purchased from 
Pocono Rabbit Farm and Laboratory Inc. (PR&L) and Jackson Laboratory, respectively. 
Rabbits and mice used for experiments were housed at PR&L and Beckman Research 
Institute of City of Hope (BRICOH), respectively. Animal procedures were performed in 
accordance with PR&L and BRICOH Institutional Animal Care and Use Committee and 
Institutional Biosafety Committee protocols.
2.2. Cells and virus
Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK-293) cells, HEK-293 
cells stably expressing Epstein-Barr virus nuclear protein 1 for enhanced ability to produce 
recombinant proteins (HEK-293–6E), human umbilical vein endothelial cells (HUVEC), 
human foreskin fibroblast 1 (HFF-1) cells, mouse myeloma cells (P3X63Ag8.653), and B 
cells derived from the pleural effusion of a patient with undifferentiated lymphoma (MC116) 
were purchased from American Type Culture Collection (ATCC, Manassas, VA). 
Doxycycline-inducible iSLK cells harboring recombinant KSHV.219 expressing enhanced 
green fluorescent protein from the human elongation factor-1α promoter (iSLK-rKSHV-
eGFP.219) [19] were obtained from Dr. D. Dittmer, University of North Carolina–Chapel 
Hill. CHO, HEK-293, and HFF-1 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM). P3X63Ag8.653 and MC116 cells were cultured in Roswell Park 
Memorial Institute medium 1640 (RPMI). Hybridomas were cultured in DMEM 
supplemented with nonessential amino acids (ThermoFisher, Waltham, MA) as described 
[20]. iSLK-rKSHV-eGFP.219 cells were cultured in DMEM as described [19]. All media 
were supplemented with 10% heat-inactivated fetal bovine serum (FBS; MilliporeSigma, 
Burlington, MA), 1% L-glutamine, and 2% penicillin-streptomycin (ThermoFisher). 
HEK-293–6E cells were cultured in Freestyle F17 Expression media without FBS (Thermo-
Fisher). HUVEC cells were cultured in endothelial cell growth ready-to-use media 
(PromoCell, Edmonton, Alberta). Cell lines were routinely tested for mycoplasma using 
PCR and shown to be negative.
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Virus was produced from iSLK-rKSHV-eGFP.219 cells and purified as described [21]. 
Purified viruses were quantified by titration in each of the cell types used in infection and 
neutralization assays.
2.3. Antibodies
Primary mouse monoclonal immunoglobulin G2a (IgG2a) anti-gpK8.1 (clone 4A4; Santa 
Cruz Biotechnology, Dallas, TX) [22], which detects the gpK8.1 ectodomain (ED), was used 
for fluorescence-activated cell sorting (FACS), immunoblot, and enzyme-linked 
immunosorbent assay (ELISA). Primary polyclonal rabbit anti-Newcastle disease virus 
(NDV) detecting nucleoprotein (NP) was a gift of Dr. T. Morrison, University of 
Massachusetts Medical School, Worcester. Primary polyclonal goat anti-human IgG Fc or 
rabbit anti-2A peptide were purchased from ThermoFisher and MilliporeSigma, respectively. 
Primary monoclonal anti-bodies (mAbs) anti-gpK8.1 (clone 41E7) and anti-gH/gL (clones 
54A1, 57C12) were generated and characterized as outlined below and used in immunoblot 
and ELISA. HRP-conjugated secondary antibodies goat anti-mouse IgG and goat anti-rabbit 
IgG (MilliporeSigma) were used for immunoblot and ELISA. Goat Fab-2 anti-mouse IgG 
(H+L) cross-adsorbed secondary antibody, conjugated to Alexa Fluor 488 (AF488) 
(ThermoFisher) was used for FACS.
2.4. Construction of plasmids to generate KSHV-LPs
To generate polyvalent KSHV-LP vaccine candidates incorporating multiple KSHV proteins 
(gpK8.1, gB, gL, and gH), two cDNAs were constructed and synthesized (Genewiz, South 
Plainfield, NJ). Each sequence included the gpK8.1 ED fused to NDV fusion protein (F) 
transmembrane/cytoplasmic (TM/CT) domains (gpK8.1-F); gB ED fused to NDV F-TM/CT 
(gB-F); full-length wild-type gL without an F-fusion (WTgL); and gH ED fused to NDV F-
TM/CT (gH-F). In one cDNA, each NDV F-TM/CT domain also contained heptad region 2 
to support trimerization of the glycoproteins; in the other cDNA, it did not (+/−HR2). To 
express this complex in its native form, unique 2A-linker sequences (18 amino acids long) 
from picornavirus [23] were interspersed between individual glycoprotein cDNAs (Table 1). 
These unique 2A-linkers were recently designed to facilitate expression of a human 
cytomegalovirus (CMV) envelope glycoprotein pentameric complex in a modified vaccinia 
Ankara-based vaccine formulation [24]. In the present study, use of 2A-linkers yielded a 
polycistronic plasmid with cleavage sites that allow gpK8.1-F, gB-F, WTgL, and gH-F to be 
processed independently after translation and released to natively incorporate on KSHV-LP 
envelopes. The two synthesized chimeric cDNAs (gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F
+/−HR2) were cloned into pCAGGS mammalian expression plasmid. Plasmids encoding for 
chimeric protein of a truncated LANA1 (aa 937–1123) fused to full-length NDV NP and 
full-length wild type LANA1 (aa 1–1123) were also synthesized and cloned into a pCAGGS 
vector. All plasmids generated for this study are summarized in Table 2. Plasmids encoding 
full-length NDV NP and M cloned into pCAGGS have been described [25]. Both NP and M 
proteins support KSHV-LP formation. Sanger sequencing was used to verify sequence 
fidelity of all synthesized and cloned constructs (primer sequences listed in Table 3).
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2.5. Transfection and generation of stable KSHV-LP-producing cells
To generate gpK8.1-gB-gL-gH KSHV-LPs, 2 µg pCAGGS-gpK8.1-F-2A-gB-F-2A-
WTgL-2A-gH-F+/−HR2 plasmid was transiently transfected into CHO or HEK-293 cells 
using linear polyethylenimine (PEI) transfection reagent (ThermoFisher). After 48 h, cells 
were stained with anti-gpK8.1 (4A4) primary antibody for 30 min, washed three times with 
phosphate-buffered saline (PBS), and stained with AF488-goat anti-mouse secondary 
antibody. FACS was used to detect surface expression of gpK8.1; untransfected and 
unstained CHO or HEK-293 cells served as negative controls. Upon confirmation of gpK8.1 
expression in both CHO and HEK-293 cells, only CHO cells were then co-transfected as 
above with individual pCAGGS-gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F+/−HR2 and pCI-
puro plasmids, followed by 5 µg/ml puromycin selection 48 h post-transfection, to generate 
stable cells expressing the four glycoproteins. Stable CHO cells resistant to puromycin 
selection were pooled and stained with primary anti-gpK8.1 mAb (4A4), followed by 
secondary goat Fab-2 anti-mouse IgG (H+L) conjugated to AF488 and sorted five times to 
generate a colony of CHO cells expressing mainly gpK8.1-gB-WTgL-gH+/−HR2 (~50% 
anti-gpK8.1-AF488 positive). Stable cells were then co-transfected with 2 µg/µl each 
pCAGGS-NDV M and pCAGGS-NDV NP plasmids to produce gpK8.1-gB-gH/gL+/−HR2 
VLPs (KSHV-LPs +/−HR2). Additional KSHV-LPs were also produced by transiently co-
transfecting CHO or HEK-293 cells with pCAGGS-NDV M, pCAGGS-NDV NP, or 
polycistronic pCAGGS-gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F+/−HR2 plasmids.
2.6. Purification and characterization of KSHV-LPs
Supernatants from stable cells releasing KSHV-LPs were collected 24–120 h post-
transfection and combined, then cell debris was removed by centrifugation (Corning 500 ml 
centrifuge tubes, SX4750 rotor, 3,724 xg, 15 min, 4 °C). To pellet KSHV-LPs, the resultant 
supernatant was ultracentrifuged (Beckman Coulter type-19 fixed-angle aluminum rotor, 
9,846 xg, 12 h, 4 °C). The resultant pellet was sucrose-gradient purified as described [26].
2.7. Construction, purification, and characterization of KSHV gpK8.1, gB, and gH/gL 
proteins
To construct KSHV gpK8.1, gB, and gH/gL Fc-6xHis tagged plasmids, the coding sequence 
for each protein ED was PCR-amplified with gene-specific primers (Table 3) from 
previously described pCAGGS-gpK8.1, pCAGGS-gB, and pCAGGS-gH/gL constructs [26]. 
The upstream (5′ ) and downstream (3′ ) primers contained NotI and SpeI enzyme 
restriction sites (gpK8.1 and gB), respectively, or Gibson assembly primers (gH/gL) [27], 
which were used to subclone PCR products into the pCMVi-SV40ori-Fc-His plasmid 
(Addgene #72065, Watertown, MA), a gift from Dr. W. Wojtowicz, Stanford University, 
Palo Alto, CA.
Fc-6xHis-tagged recombinant KSHV gpK8.1, gB, and gH/gL proteins were expressed via 
transient transfection of HEK-293–6E cells using PEI and protein purified as described [28].
2.8. Generation and identification of KSHV-glycoprotein-specific mAbs
mAbs specific to KSHV gpK8.1 and gH/gL were generated using standard techniques [20]. 
Briefly, we immunized four wild-type BALB/c mice intraperitoneally with 100 µg complete 
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Freund’s adjuvant (MilliporeSigma F5881) mixed with 50 µg purified UV-inactivated 
rKSHV-eGFP.219 (UV-KSHV) resuspended in 200 µl TNE buffer. Mice were boosted five 
times with 100 µg incomplete Freund’s adjuvant (MilliporeSigma F5506) and 25 µg UV-
KSHV resuspended in 200 µl TNE buffer every two weeks. Once optimal antibody response 
to gpK8.1 and gH/gL in sera was confirmed using ELISA, a sixth booster immunization was 
provided intravenously with 25 µg UV-KSHV resuspended in 200 µl TNE buffer. Boosted 
mice were sacrificed and splenocytes were isolated and fused with a mouse myeloma cell 
line (P3X63Ag8.653) to generate murine hybridomas, using a standard polyethylene glycol 
(PEG) method, then cultured and screened for positive (gpK8.1 or gH/ gL) clones as 
described [20]. Positive hybridomas were expanded, hybridoma secreted antibodies bulk-
purified through protein A spin-columns (Clontech, Mountain View, CA), and used for 
ELISA, FACS, and immunoblot.
2.9. SDS-PAGE, Coomassie staining, and immunoblotting
Cells or KSHV-LPs were lysed in RIPA buffer (MilliporeSigma). Lysed suspensions were 
vigorously vortexed, incubated for 30 min on ice and processed for immunoblot (i.e., 
gpK8.1, gB, gH/ gL, NDV NP, and 2A or Fc-tagged protein expression), followed by 
detection with relevant primary and secondary antibodies as described [26].
2.10. Transmission electron microscopy (TEM)
To assess the composition of KSHV-LPs compared to wild-type KSHV, morphological 
examination was conducted using TEM. Purified KSHV-LPs +/−HR2 and rKSHV-eGFP.219 
virus were fixed in 4% paraformaldehyde, prepared, and analyzed using TEM as described 
[29].
2.11. Immunization of rabbits and collection and processing of sera
Rabbits (8–10 weeks-old) were immunized subcutaneously (Days 0, 21, 42) with 50 µg total 
protein of purified KSHV-LPs +/−HR2 (n = 6/group) in 0.5 ml TNE buffer adsorbed to 500 
µg aluminum hydroxide (alum) mixed with 50 µg monophosphoryl lipid A from Salmonella 
enterica serotype Minnesota Re595 (MPL) as adjuvants; alum/MPL-adjuvanted UV–KSHV 
(n = 6) or alum/MPL-adjuvanted TNE (n = 6) served as positive and negative controls, 
respectively. Rabbits were bled before immunization (pre-bleed baseline) and on Days 14, 
35, 49, 70, and 90 (terminal bleed).
2.12. Measurement of anti-gpK8.1-, gB-, and gH/gL-specific antibody titers in sera from 
immunized rabbits
Using sera collected from rabbits, antibodies titers were assessed by ELISA, using 
individual purified glycoproteins as targets as described [26].
2.13. Purification of IgG antibodies from rabbit sera and determination of anti-gpK8.1-, 
gB-, and gH/gL-specific antibody titers
Purification of IgG antibodies was conducted by pooling Day 49 sera (highest antibody titer) 
from immunized rabbits (n = 6) from each of the four treatment/control groups. Pooled sera 
were diluted 1:10 in equilibration/binding/wash buffer (1.5 M glycine, 3 M NaCl, pH 9.0) 
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and purified through protein A spin-columns. Purified IgG concentration was determined 
using nanodrop. IgGs were separated using SDS-PAGE and stained with Coomassie to 
determine purity. ELISA was used to determine titers of anti-gpK8.1-, gB-, and gH/gL-
specific antibodies from purified IgGs at various concentrations (25, 12.5, 6.25, 3.125, and 
1.56 µg/ml). IgGs were stored at 4 °C until use in subsequent experiments.
2.14. In vitro neutralization assay
In vitro neutralization was performed using various cell types of human origin, namely 
epithelial, fibroblast, endothelial, or B cells, as described [26].
2.15. Statistics
Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San 
Diego, CA). Multiple comparisons between groups were calculated using Kruskal-Wallis, 
whereas differences between groups were computed using Dunn’s post-hoc test and Mann-
Whitney U test. All statistical tests were two-tailed; p-values ≤ 0.05 were considered 
significant. IC50 (µg/ml) values were calculated based on neutralization of KSHV.219 by 
purified IgGs in HEK-293, HFF-1, HUVEC, and MC116 cells using nonlinear, dose-
response regression analysis.
3. Results
3.1. Construction, purification, and characterization of KSHV-LP vaccine candidates that 
incorporate four KSHV glycoproteins
To make multivalent KSHV-LPs, we constructed two versions of a single polycistronic 
plasmid encoding sequences for four glycoproteins, designated pCAGGS-gpK8.1-F-2A-gB-
F-2A-WTgL-2A-gH-F+/−HR2 (Fig. 1a). We fused the EDs of three KSHV glycoproteins 
(gpK8.1, gB, and gH) to the structural protein NDV F with or without its HR2 domain, 
which supports protein trimerization and increases the number of immunogens per KSHV-
LP [30]. We incorporated full-length wild-type KSHV gL because it does not have a 
transmembrane domain and depends on gH for transport to the virion surface [31]. The 
glycoproteins were interspersed with a picornavirus 2A self-cleaving peptide for efficient 
expression and cleavage under a single CMV promoter [24,32].
To confirm plasmid DNA transfection efficiency and expression of various glycoproteins 
from the polycistronic plasmids, we transiently transfected each plasmid into CHO or 
HEK-293 cells, two epithelial cell lines widely used for protein expression. To confirm 
gpK8.1 cell surface expression, we stained transfected cells with anti-gpK8.1 primary 
antibody and AF488-conjugated secondary antibody, then used FACS to detect gpK8.1 
expression. We used the previously constructed pCAGGS-gpK8.1-F+HR2 plasmid as a 
positive control for gpK8.1 expression [26]; untransfected cells and unstained transfected 
cells served as negative controls. Transfected CHO and HEK-293 cells expressed gpK8.1 
(Fig. 1b). However, gpK8.1 was expressed in fewer total cells transfected with polycistronic 
plasmids compared to cells transfected with plasmid encoding for a single protein; for 
example, in CHO cells transfected with gpK8.1-F-2A-gB-F2A-WTgL-2A-gH-F −HR2 or 
+HR2, gpK8.1 expression was 4.74% and 6.77%, respectively, compared to 31.8% in CHO 
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cells transfected with pCAGGS-gpK8.1-F+HR2. This occurred despite optimization of 
transfection efficiency using various ratios of DNA:PEI or other transfection reagents (data 
not shown), and is probably due to the large cDNAs cloned into the plasmids.
To overcome poor transfection efficiency and improve KSHV-LP production for full 
characterization and immunogenicity testing, we established CHO cells that stably expressed 
each multicistronic plasmid. We used only CHO cells because > two-thirds of recombinant 
therapeutic agents on the market are generated in CHO cell lines [33], and because no 
adventitious human pathogen, a major concern to regulatory authorities, has been reported 
for CHO cells, in contrast to cell lines of human origin [34]. We co-transfected CHO cells 
with pCAGGS-gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F+/−H R2 and pCI-puro. We selected 
transfected cells in puromycin, stained puromycin-resistant cells with anti-gpK8.1-AF488 
antibody, and performed FACS sorting five times to enrich for gpK8.1-expressing cells (Fig. 
2a). Selection was based on gpK8.1 due to lack of well-validated mAbs against other KSHV 
glycoproteins at the time we made the stable cell lines.
To produce KSHV-LPs, we co-transfected enriched stable cells with both pCAGGS-NDV M 
and pCAGGS-NDV NP, then collected supernatants from transfected cells daily, from 24 to 
120 h post-transfection. We purified KSHV-LPs from supernatants using sucrose-gradient 
sedimentation, followed by floatation gradients (Fig. 2b), then fully characterized their 
composition and structure as described [26]. In brief, we used anti-2A, anti-NDV, anti-
gpK8.1, and anti-gH/gL antibodies in immunoblot to show that all components (i.e., KSHV 
glycoproteins and NDV structural proteins) were incorporated and packaged into KSH-
VLPs (Fig. 2c). Because the 2A sequence between WTgL and gH-F is cleaved and remains 
with WTgL, it is not possible to use the anti-2A antibody to detect gH. Thus, to further 
confirm the specificity of the gpK8.1 protein bands (55 and 70 kDa) and also detect gH/gL 
protein complex (130 kDa), we used the specific mAbs anti-gpK8.1 (41E7) and anti-gH/gL 
(57C12), generated in our laboratory, to detect individual proteins (Fig. 2c). To our 
knowledge, there is no commercially available KSHV anti-gB antibody. Thus, it was not 
feasible for us to unequivocally prove the presence of gB (110 kDa) in the KSHV-LPs. 
However, the molecular weights we identified for each individual protein in the KSHV 
subunit vaccines agreed with published data [13], providing strong evidence that KSHV-LPs 
generated from a polycistronic plasmid are faithful to the composition of the subunits. We 
used electron microscopy to confirm that the size, shape, and morphology of KSHV-LPs 
were similar to rKSHV-eGFP.219 virus: KSHV-LP diameters were 100 nm, with a spherical 
shape and spike-like structures, resembling glycoproteins incorporated into the virions (Fig. 
2d).
3.2. Rabbits immunized with KSHV-LPs +/−HR2 elicited high-titer KSHV-glycoprotein-
specific antibody responses
To demonstrate the ability of multivalent KSHV-LPs to induce KSHV-glycoprotein-specific 
antibody responses, we immunized rabbits with alum/MPL-adjuvanted KHSV-LPs +/−HR2, 
then used ELISA to determine antibody titers and kinetics over time. Adjuvants were used to 
improve humoral and cellular immunogenicity [38,39];selection of the alum/MPL 
formulation was based on AS04, an adjuvant licensed for human use currently being used in 
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two licensed VLP-based vaccines, the human papillomavirus vaccine Cervarix® 
(GlaxoSmithKline) [35] and the hepatitis B vaccine FEN-Drix® (GlaxoSmithKline) [36]. 
Because there is no gold standard for measuring IgGs against KSHV infection in humans or 
immunized animals, due to the inconsistent detection of KSHV-specific protein IgGs in 
KSHV-infected individuals, we used purified proteins as binding targets for use in ELISA, as 
described [37]. To do this, we used our recently constructed plasmids that individually 
encode for soluble gpK8.1, gB, or gH/gL proteins to produce the proteins and confirmed 
their authenticity using Coomassie and immunoblot (Fig. 3a).
To characterize antibody immune responses, rabbits were immunized subcutaneously three 
times (Days 0, 21, 42) with 50 µg purified KSHV-LPs +/−HR2 suspended in 0.5 ml TNE 
buffer adsorbed to 500 µg alum/50 µg MPL. Rabbits immunized with 50 µg purified UV-
KSHV or TNE, adjuvanted with alum/MPL, served as positive and negative controls, 
respectively. To obtain enough sera to support complete characterization of antibody 
responses, we used 6 rabbits/group. To assess short- and long-term antibody responses, 
rabbits were bled to obtain sera seven days before the first immunization (pre-bleed) and on 
Days 14, 28, 35, 49, 70, and 90 (terminal bleed) (Fig. 3b). We used ELISA to determine 
KSHV-glycoprotein-specific antibody titers from individual animals over time using the 
purified proteins described above as the binding targets. All rabbits immunized with KSHV-
LPs +/−HR2 or UV-KSHV generated KSHV-glycoprotein-specific IgG antibody responses 
that increased following booster immunizations, compared to TNE-immunized rabbits or 
pre-bleeds (negative controls) (Fig. 3c). The increase in KSHV glycoprotein-specific 
antibody response peaked by Day 49, after the second booster immunization. There was no 
difference in the titers of glycoproteins (K8.1, gB, or gH/gL) between rabbits immunized 
with KSHV-LPs+HR2 or −HR2. Compared to either KSHV-LP +/−HR2, UV-KSHV 
immunization elicited significantly higher titers of KSHV-glycoprotein-specific antibodies, 
which remained high through Day 90. In contrast, antibody titers from animals immunized 
with either KSHV-LP +/−HR2 dropped by Day 70 (Mann-Whitney test; gpK8.1 Day 49 vs 
Day 70: KSHV-LPs −HR2 p = 0.0022, KSHV-LPs +HR2 p = 0.0022; gB Day 49 vs Day 70: 
KSHV-LPs −HR2 p = 0.0022, KSHV-LPs+HR2 p = 0.0022; gH/gL Day 49 vs Day 70: 
KSHV-LPs −HR2 p = 0.0043, KSHV-LPs+HR2 p = 0.0303), suggesting that long-term 
antibody responses in KSHV-LP +/−HR2-immunized rabbits are weaker than those of UV-
KSHV-immunized rabbits.
3.3. KSHV-LPs +/−HR2 elicit robust nAbs that prevent rKSHV-eGFP.219 infection in 
diverse cell types
To measure the ability of KSHV-glycoprotein-specific polyclonal antibodies in sera from 
rabbits immunized with multivalent KSHV-LPs to neutralize viral infection and to reduce 
the previously observed serum effect [26,29,40], we first pooled (6 rabbits/group) and 
purified IgGs from Day 49 samples (highest titers), then quantified KSHV-glycoprotein-
specific IgGs using ELISA (Fig. 4a). Similar to unpurified sera, titers for gpK8.1-, gB-, and 
gH/gL-specific IgGs were significantly higher in rabbits immunized with purified KSHV-
LPs +/−HR2 compared to TNE (negative control) using a non-parametric Kruskal-Wallis 
test (gpK8.1, p = 0.0003; gB, p = 0.0002; gH/gL, p = 0.0012). KSHV-specific IgG titers 
were higher in rabbits immunized with KSHV-LPs-HR2 than KSHV-LPs+HR2; for 
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example, at 25 µg/ml, gpK8.1, gB, and gH/gL IgG titers were 4-fold higher. However, titers 
were highest in rabbits immunized with UV-KSHV. For example, at 25 µg/ml, gpK8.1, gB 
and gH/gL IgG titers for UV-KSHV were 3-fold and 10-fold higher than in KSHV-LP-HR2 
and KSHV-LP+HR2 IgG-purified samples, respectively (Fig. 4a).
After confirming the presence and titers of KSHV-glycoprotein specific antibodies in 
purified sera, we performed neutralization activity assays in diverse cell types that represent 
most of the typespermissive to KSHV infection in vivo. First, we titrated purified rKSHV-
eGFP.219 in four permissive cell types of human origin to determine volumes that ensured > 
20% rKSHV-eGFP.219 infectivity for in vitro neutralization (Fig. 4b, Panel i). To conduct in 
vitro neutralization assays, we incubated serially diluted purified IgGs (12.5, 25, 50, or 100 
µg/ml) with rKSHV-eGFP.219. We measured the percentage of eGFP+ cells (i.e., KSHV-
infected cells) using FACS and defined an effective neutralization titer as 50% inhibition of 
infection, after normalization to control IgG samples from TNE–immunized rabbits. When 
rKSHV-eGFP.219 virus was pre-incubated with serially diluted concentrations of total 
purified IgG antibodies (12.5, 25, 50, or 100 µg/ml) from TNE-immunized rabbits (negative 
control), all concentrations achieved ~8% neutralizing activity (serum effect) in a non-dose-
dependent manner in HEK-293 cells (data not shown). Thus, we used 8% as the 
normalization percentage to account for the serum effect in all subsequent neutralization 
assays. In contrast, rKSHV-eGFP.219 pre-incubated with serially diluted concentrations of 
pooled purified IgGs from rabbits immunized with KSHV-LPs +/−HR2 or UV-KSHV 
resulted in a dose-dependent reduction of KSHV infection in an endothelial cell line 
(HUVEC), foreskin fibroblast cell line (HFF-1), and B cell line (MC116) (Fig. 4b, Panel ii). 
Interestingly, despite UV-KSHV-immunized rabbits having higher titers of KSHV-
glycoprotein-specific IgGs than KSHV-LP-immunized rabbits (Fig. 4a), the purified IgGs 
showed no statistical differences in nAb activities in any cell line tested (Fig. 4b). At the 
highest dilution analyzed (100 µg/ml), UV-KSHV and both KSHV-LPs +/−HR2 neutralized 
KSHV infection by 60–90% in all cell types tested (Fig. 4b, Panel ii). Importantly, even at 
the lowest concentration, IgGs from any of the vaccine candidates neutralized KSHV 
infection by 12–55%, in all cell types tested, with the highest neutralization activity 
observed in HFF-1 cells. The calculated concentration required to block 50% of infection 
(IC50; Table 4) varied between cell lines and vaccine candidates: UV-KSHV, 14.07–28.89 
µg/ml; KSHV-LPs −HR2, 26.56–37.97 µg/ml; and KSHV-LPs+HR2, 29.57–49.64 µg/ml. 
Our results confirm that a select group of KSHV glycoproteins incorporated on the surface 
of KSHV-LPs, and administered with appropriate adjuvants, can stimulate nAbs that block 
KSHV infection of diverse cell types in vitro.
4. Discussion
Envelope glycoproteins that mediate viral entry into permissive cells are recognized as key 
targets for eliciting nAbs for most licensed subunit vaccines [41], and thus offer an ideal 
strategy for developing protective subunit prophylactic vaccines against oncogenic KSHV. In 
this study, we generated multivalent vaccine candidates that incorporate four key KSHV 
envelope glycoproteins (gpK8.1, gB, and gH/gL) known to mediate viral infection into a 
single KSHV-LP to elicit potent nAbs in immunized animals [14,17,42]. We showed our 
newly generated multivalent KSHV-LPs to be immunogenic, eliciting moderate titers of 
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antibodies specific to gpK8.1, gB, and gH/gL. Importantly, we showed for the first time that 
purified IgGs from pooled sera of rabbits immunized with KSHV-LPs neutralized KSHV 
infection in four permissive cell types (epithelial, endothelial, fibroblasts, and B cells), 
comparable to purified IgGs from UV-KSHV immunized rabbits.
The co-expression of a single construct comprising four KSHV glycoproteins, interspersed 
with 2A self-cleaving peptide for efficient expression and cleavage under a single promoter 
[32], and NDV NP and M proteins resulted in the successful self-assembly and release of 
KSHV-LPs. Purified KSHV-LPs from CHO cells structurally resembled purified KSHV 
virions in size, shape, and morphology. In addition, we confirmed that all four KSHV 
glycoproteins were incorporated into the KSHV-LPs. These data confirm that we generated a 
bona fide multivalent KSHV-LP expressing four glycoproteins as a reagent for immunization 
of animals.
To confirm the immunogenicity of the newly developed subunit KSHV-LP vaccine 
candidates and to measure their ability to elicit robust and potent broadly nAbs, we 
immunized rabbits with alum/MPL-adjuvanted KSHV-LPs+/−HR2 and compared antibody 
response kinetics over time with rabbits immunized with alum/ MPL-adjuvanted UV-KSHV. 
We detected IgG antibody titers specific to all four KSHV glycoproteins in sera from rabbits 
immunized with KSHV-LPs +/−HR2, which peaked by Day 49 after the second boost, but 
dropped significantly by Day 70. This was in contrast to sera from UV-KSHV-immunized 
rabbits, which maintained high titers throughout all time-points tested, suggesting that the 
durability of antibodies in KSHV-LP-immunized animals is sub-optimal. The current 
findings of low immunogenicity of KSHV-LPs relative to UV-KSHV are consistent with our 
previous studies in KSHV and Epstein-Barr virus [26,29], and other reported studies in foot-
and-mouth disease virus, Chikungunya, and Zika virus [43–45], comparing VLP-based 
vaccines with inactivated virus.
As a first step in dissecting the ability of our candidate vaccine to elicit robust nAbs, we 
performed in vitro neutralization in epithelial cells, endothelial cells, fibroblasts, and B cells. 
To reduce the serum effect that has been observed when using total serum to perform 
neutralization [26,29], we purified total IgGs, and showed that incubation of purified IgGs 
from KSHV-LP+/−HR2- or UV-KSHV-immunized rabbits with rKSHV-eGFP.219 reduced 
infection in a dose-dependent manner in all cell types tested. Surprisingly, despite purified 
IgGs from UV-KSHV immunized rabbits having higher titers of KSHV-glycoprotein-
specific antibodies in sera or in purified IgGs, the neutralization activities between KSHV-
LPs +/−HR2 and UV-KSHV were comparable at Day 49. The mechanism behind this 
observation remains under investigation in our laboratory. We predict that future 
optimization of vaccine parameters, including vaccine dose, frequency of immunization, 
immunization route, or the use of other robust vectors (e.g., modified vaccinia Ankara vector 
or adenovirus vector) to deliver KSHV-LPs or wild-type KSHV glycoproteins as live-
attenuated vaccines, will elicit high titers of potent nAbs that could block infection in both in 
vitro and in vivo infection models better than those found in UV-KSHV immunized rabbits.
Despite the public health burden of KSHV infection globally, to date, no KSHV subunit 
vaccine candidate has been tested in preclinical animal models, apart from our single study 
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[26], or in clinical trials, making it difficult to compare our current results with other studies. 
Therefore, to assess the efficacy of our vaccine and allow comparison with previous studies 
for other viruses, we analyzed neutralization activity based on IC50 values for KSHV-LPs in 
all cell types tested (Table 4). Despite the observed neutralization, the potency of the purified 
KSHV IgGs was low compared to other neutralizing IgGs raised in various species against 
different viruses and pathogens [46,47]. For example, HIV IgGs targeting the major 
immunodominant envelope gp120 trimer, purified from either infected individuals or 
immunized cows blocked infection with IC50 <1 µg/ml [46,47]. Similar results have been 
observed for Plasmodium falciparum [48], hepatitis C virus [49], Zika virus [50], and CMV 
[51]. However, it is important to note that in the case of KSHV-LPs, we used total purified 
IgGs to calculate IC50, whereas in the other reported cases, IC50 was calculated using 
antigen-specific IgGs. Future studies should include purifying or isolating KSHV 
glycoprotein-specific nAbs from animals immunized with KSHV-LPs for fair comparison.
Previous studies have shown that the trimerization of HIV envelope glycoproteins (gp120 
and gp41), respiratory syncytial virus F glycoprotein, or influenza hemagglutinin 
glycoprotein improved the stability of these proteins and enhanced their immunogenicity as 
subunit vaccines, resulting in the induction of potent broadly nAbs [52–54]. In the current 
study, the use of the NDV F HR2 domain, which supports trimerization of the proteins 
(gpK8.1, gB and gH) and increases the number of immunogens per individual KSHV-LP, 
was not advantageous, as both KSHV-LPs +/−HR2 neutralized KSHV equally in all cell 
types tested, with - HR2 performing somewhat better than+HR2.
In nature, KSHV only infects humans; however, reports indicate that a humanized mouse 
model harboring functional human immune system components, and the common marmoset 
(Callithrix jacchus), a non-human primate model, can be infected with KSHV [55,56]. These 
two animal models open up potential new frontiers for elucidating KSHV biology, including 
latent infection, associated diseases, and B-cell- and T–cell-mediated immune responses in 
vivo [55–57]. Thus, as a pre-requisite for performing Phase I clinical trials, we envision that 
future studies to elucidate correlates of immune protection in these two models will allow 
optimization of various vaccine parameters and define correlates of immune protection. In 
summary, our results demonstrate the successful generation and characterization of 
multivalent subunit KSHV-LPs as immunogenic vaccine candidates that produce antibody 
responses in rabbits capable of neutralizing KSHV in vitro in diverse cell types.
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Fig. 1. 
Construction and expression of polycistronic plasmids expressing four KSHV glycoproteins. 
(a) Schematic representation of pCAGGS-gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F−/+HR2 
plasmids (not drawn to scale). A single transcript was synthesized to express the gpK8.1 
ectodomain (ED) fused to NDV fusion protein (F) transmembrane/cytoplasmic (TM/CT) 
domains (gpK8.1-F), the gB ED fused to NDV F-TM/CT (gB-F), and the gH ED fused to 
NDV F-TM/CT (gH-F), each with or without heptad region 2 (+/−HR2), and with full-
length wild-type gL (WTgL) inserted between the gB and gH sequences. Sequence fidelity 
was confirmed using Sanger sequencing. The numbers shown represent corresponding 
amino acid numbers of the EDs. (b) Expression of gpK8.1-gB-WTgL-gH−/+HR2 in 
HEK-293 and CHO cells. 106 cells from HEK-293 or CHO cells were seeded in a six-well 
plate and transfected with 2 µg pCAGGS-gpK8.1-F-2A-gB-F-2A-WTgL-2A-gH-F−/+HR2 
or pCAGGS-gpK8.1-F+HR2 (positive control). Transfection efficiency was evaluated 48 h 
post-transfection by staining transfected HEK-293 and CHO cells with gpK8.1 mAb, 
followed by secondary antibody goat anti-mouse IgG conjugated to AF488. Unstained cells, 
cells stained with secondary antibody alone (isotype control), and un-transfected cells served 
as negative controls, and gpK8.1-transfected cells served as positive control. Cells were 
analyzed using FACS by acquiring 10,000 events.
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Fig. 2. 
Generation of stable CHO cells expressing gpK8.1-gB-WTgL-gH+/−HR2 proteins and 
production and characterization of purified KSHV-LPs. (a) Generation of stable CHO 
gpK8.1-gB-WTgL-gH+/−HR2 cells. CHO cells were co-transfected with 2 µg pCAGGS-
gpK8.1[…] and pCI-puro plasmids. Forty-eight h post-transfection, cells were maintained in 
selection media supplemented with puromycin (5 µg/ml) until colonies of puromycin-
resistant cells were formed. Stable cells were harvested, re-suspended in 1 × PBS and 
stained as in Fig. 1b. Stained cells were live-sorted using FACS five times to a purity of 
~50% of gpK8.1-expressing cells. (b) Schematic showing the production of KSHV-LPs. 
KSHV gpK8.1-gB-WTgL-gH+/−HR2 stable CHO cells were co-transfected with pCAGGS 
NDV NP and pCAGGS NDV M plasmids. Supernatants from transfected cells were 
collected and clarified and KSHV-LPs were pelleted and sucrose-gradient purified as 
described in Methods. (c) Immunoblot analysis of purified KSHV-LPs. Un-transfected CHO 
cells, KSHV gpK8.1-gB-WTgL-gH+/−HR2 stable CHO cells (CHO KSHV-LPs+/−HR2), 
and purified KSHV-LPs+/−HR2 were resolved on a 4–12% SDS polyacrylamide gel, 
transferred to a polyvinylidene fluoride membrane, and analyzed by immunoblot using 
rabbit polyclonal (anti-2A or anti-NDV) or mouse monoclonal (anti-gpK8.1 or anti-gH/gL) 
antibodies as indicated. pCAGGS encoding for NDV NP fused to LANA1 and pCAGGS 
LANA1 were used as negative controls. (d) Structural and morphological characterization of 
KSHV-LPs by TEM. rKSHV-eGFP.219 and KSHV-LPs+/−HR2 were fixed in 4% 
paraformaldehyde and absorbed to glow-discharged, carbon-coated, 200-mesh EM grids. 
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EM images were collected using an FEI Tecnai 12 TEM and recorded with a Gatan 2 × 2 k 
CCD camera at a magnification of 21,000X and a defocus value of ~1.5 µm.
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Fig. 3. 
KSHV-glycoprotein-specific IgG titers in immunized New Zealand white rabbits. (a) 
Coomassie stain (left) and immunoblot (right) of KSHV gpK8.1, gB, and gH/gL 
recombinant Fc-His tagged proteins. Fc-6xHis-tagged recombinant KSHV gpK8.1, gB, and 
gH/gL proteins were expressed by transiently transfecting HEK-293–6E cells. Culture media 
was harvested six days post-transfection by centrifugation and filtration through a 0.22 µM. 
Fc-6xHis-tagged KSHV proteins in the media were purified using protein A spin-columns, 
concentrated in PBS using Amicon Ultra 15 centrifugal filter units, and quantified using a 
nanodrop spectrophotometer. To confirm the specificity of the proteins, the concentrated 
proteins were separated on a 4–12% SDS-PAGE and detected by Coomassie blue stain (for 
molecular weight) or transferred to a polyvinylidene fluoride membrane for immunoblot 
analysis using monoclonal anti-gpK8.1 or anti-gH/gL or polyclonal goat anti-human Fc (gB) 
antibodies as indicated. (b) Immunization and bleeding schedules of wild-type New Zealand 
white rabbits. Eight- to 10-week-old rabbits (n = 6/treatment) were immunized 
subcutaneously at Days 0, 28 and 42 with 50 µg purified KSHV-LPs−/+HR2, UV-inactivated 
KSHV, or TNE buffer, all adsorbed to alum and MPL as adjuvants. Immunized rabbits were 
bled seven days pre-immunization (−7) and on Days 14, 35, 49, 70, and 90 (terminal bleed). 
(c) Serum KSHV glycoprotein-specific antibody responses. KSHV-glycoprotein IgG-
specific antibody titers in diluted (1:300 and 1:900) sera from immunized rabbits were 
determined using ELISA with recombinant tagged gpK8.1, gB, and gH/gL proteins; results 
of quadruplicate replicates for each of the six animals per group are expressed as mean ± 
standard deviation (SD). Differences in antibody titers between all groups were analyzed 
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using a Kruskal-Wallis test; differences between the −HR2 and+HR2 vaccine were assessed 
using a Mann-Whitney test. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.)
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Fig. 4. 
In vitro neutralization capabilities of purified IgGs from rabbits immunized with KSHV-LPs
+/−HR2 in diverse cell types. (a) Titration of purified IgGs specific to KSHV glycoproteins 
by ELISA. Purification of IgG antibodies was conducted by pooling equal amounts of Day 
49 sera from immunized rabbits (n = 6) from each of the four treatment/control, groups. 
KSHV-glycoprotein IgG-specific antibody titer was determined using ELISA with 
recombinant tagged proteins gpK8.1, gB, and gH/gL as targets; results of quadruplicate 
replicates are expressed as mean ± SD. (b) rKSHV-eGFP.219 titration and neutralization 
assays in epithelial, fibroblast, endothelial, and B cells. Panel i. rKSHV-eGFP.219 virus 
titration in diverse cell types. Individual cell lines were seeded overnight at a density of 5 × 
105 in quadruplicate in 48-well-plates. The individual cell lines were then incubated with 5, 
10, 20, 30, or 50 ml of the purified virus in a total volume of 100 µl of virus plus serum-free 
media for 24 h at 37°C. Infected cells (eGFP+) were quantified using FACS by acquiring a 
total of 10,000 events. Panel ii. Neutralization activity in HEK-293 cells, HFF-1 cells, 
HUVEC, and MC116 B cell lines. Neutralization activities were determined by incubating 
rKSHV-eGFP.219 virus and purified IgGs of varying concentrations (12.5, 25, 50, or 100 
µg/ml) from all groups of test animals for 1 h at 37 °C, before being added to previously 
seeded cells in a 48-well plate. After 1 h incubation at 37 °C, the cells were thoroughly 
washed three times with 1 × PBS before adding growth media. The level of neutralization 
was determined in the cells after 24 h using FACS to quantify the number of eGFP+cells. 
Cells incubated with virus or with media alone served as positive and negative controls, 
respectively. Results of quadruplicate replicates are expressed as mean ± SD.
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Table 4
IC50 values for UV-KSHV, KSHV-LPs −/+ HR2 purified IgGs in various cell types.
IC50 (g/ml)
Cell-line UV-KSHV KSHV-LPs–HR2 KSHV-LPs+HR2
HEK-293 27.36 33.49 39.9
HFF-1 21.41 26.56 36.24
HUVEC 28.89 28.2 29.57
MC116 14.07 37.97 49.64
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